---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-008389"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:53:51.684017+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics appoints Gabriela Gruia, M.D. to board; grants 12,500-share option

## Summary
- Board expanded from 8 to 9 directors; Dr. Gruia appointed as Class II director effective May 5, 2023.
- Option to purchase 12,500 shares at $3.86 (closing price on grant date) fully vesting in one year.
- Dr. Gruia brings 25+ years in oncology drug development; former SVP at Novartis Oncology leading 12 NME approvals.
- No familial or transaction relationships requiring disclosure; serves until 2024 annual meeting or resignation.

## SEC filing metadata
- accession: 0001558370-23-008389
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837023008389/0001558370-23-008389-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837023008389/apre-20230505x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-008389
- JSON: https://secwatch.observer/filing/0001558370-23-008389.json
- Plain text: https://secwatch.observer/filing/0001558370-23-008389.txt

## Key facts
- Executive change
  Gabriela Gruia, M.D. was appointed as Class II director at Aprea Therapeutics, Inc..
  - Action: appointed
  - Role: Class II director
  source text: On May 5, 2023, the Board of Directors (the “Board”) of Aprea Therapeutics, Inc. (the “Company”) increased the size of the Board from eight to nine directors and appointed Gabriela Gruia, M.D., as a Class II director and new member of the Board to fill the vacancy on the Board, effective immediately, to serve until the Company’s 2024 annual meeting of stockholders or until her earlier resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000155837023008389/0001558370-23-008389-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.